A new role for NFkB in immunosurveillance and its implications for cancer immunotherapy

OncoImmunology

Volumn 2, Issue 10, 2013, Pages

  Beg, Amer A ^a   Khan, Tahira ^a,b   Antonia, Scott J ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b NATIONAL UNIVERSITY OF SCIENCES AND TECHNOLOGY   (Pakistan)

Author keywords

Chemokines; Immunosurveillance; Immunotherapy; Inflammation; Lung cancer; NFkB

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1;

ARTICLE; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CROSS PRESENTATION; DRUG ACTIVITY; DRUG RESPONSE; GENE ACTIVATION; GENETIC CORRELATION; HUMAN; IMMUNOREGULATION; IMMUNOSURVEILLANCE; LUNG METASTASIS; LYMPHOCYTIC INFILTRATION; NONHUMAN; SUBCUTANEOUS TISSUE TUMOR; T LYMPHOCYTE; TUMOR MICROENVIRONMENT;

EID: 84890289977     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.25963     Document Type: Article

References (10)

1. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006; 441:431- 6; PMID:16724054; http://dx.doi.org/10.1038/ nature04870
2. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005; 5:749-59; PMID:16175180; http://dx.doi.org/10.1038/nri1703
3. Meylan E, Dooley AL, Feldser DM, Shen L, Turk E, Ouyang C, Jacks T. Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature 2009; 462:104-7; PMID:19847165; http:// dx.doi.org/10.1038/nature08462
4. Bassères DS, Ebbs A, Levantini E, Baldwin AS. Requirement of the NF-kappaB subunit p65/RelA for K-Ras-induced lung tumorigenesis. Cancer Res 2010; 70:3537-46; PMID:20406971; http://dx.doi. org/10.1158/0008-5472.CAN-09-4290
5. Hopewell EL, Zhao W, Fulp WJ, Bronk CC, Lopez AS, Massengill M, Antonia S, Celis E, Haura EB, Enkemann SA, et al. Lung tumor NF-kB signaling promotes T cell-mediated immune surveillance. J Clin Invest 2013; 123:2509-22; PMID:23635779; http://dx.doi.org/10.1172/JCI67250
6. Muthuswamy R, Berk E, Junecko BF, Zeh HJ, Zureikat AH, Normolle D, Luong TM, Reinhart TA, Bartlett DL, Kalinski P. NF-kB hyperactivation in tumor tissues allows tumor-selective reprogramming of the chemokine microenvironment to enhance the recruitment of cytolytic T effector cells. Cancer Res 2012; 72:3735-43; PMID:22593190; http://dx.doi. org/10.1158/0008-5472.CAN-11-4136
7. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006; 6:836-48; PMID:17063185; http:// dx.doi.org/10.1038/nri1961
8. Fuertes MB, Woo SR, Burnett B, Fu YX, Gajewski TF. Type I interferon response and innate immune sensing of cancer. Trends Immunol 2013; 34:67- 73; PMID:23122052; http://dx.doi.org/10.1016/j. it.2012.10.004
9. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-54; PMID:22658127; http://dx.doi.org/10.1056/NEJMoa1200690
10. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/ NEJMoa1003466